Hannover Medical School

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

Phase 3Recruiting2026150 people31 Jul 2026clinicaltrials.gov

NCT06391450

Phase 4Active, not recruiting202444 people30 Apr 2024clinicaltrials.gov

NCT02985242

Phase 4Terminated20176 people7 Dec 2016clinicaltrials.gov

NCT02728453

Phase 4Terminated20167 people5 Apr 2016clinicaltrials.gov

NCT02374567

Phase 3Terminated2015407 people2 Mar 2015clinicaltrials.gov

NCT01861951

Phase 2Completed2012120 people24 May 2013clinicaltrials.gov

NCT01424839

CollaboratorPhase 4Status unknown2011400 people29 Aug 2011clinicaltrials.gov

NCT01320254

Phase 2Completed201193 people22 Mar 2011clinicaltrials.gov

NCT01289301

Phase 4Status unknown2011124 people3 Feb 2011clinicaltrials.gov

NCT01242631

Phase 2Completed201025 people17 Nov 2010clinicaltrials.gov

NCT01096277

Phase 4Status unknown201070 people31 Mar 2010clinicaltrials.gov

NCT00402532

Phase 3Completed2005190 people22 Nov 2006clinicaltrials.gov

NCT00002532

Phase 2Status unknown199316 Feb 2004clinicaltrials.gov

Thirty Years and Beyond: Long-term Outcomes After Liver Transplantation at a Single Center: Progress, Challenges, and Future Implications

Transplantation direct24 Sept 2026